Nevro Brand Guidelines: Redwood City’s 10 kHz Spinal Cord Stimulation Maker & Globus

A spinal cord stimulation company from Redwood City.

Nevro is a medical device company headquartered in Redwood City, California, a city between San Francisco and San Jose. The trade site MedCity News reported in April 2016 that the company was founded in 2006 and had been led since 2011 by Michael DeMane, formerly chief operating officer of Medtronic. Its field is spinal cord stimulation, or SCS: small electrodes on leads placed near the spinal cord, connected to a compact battery-powered generator implanted under the skin, as MedCity News described the Senza system in the same report.

The idea behind the company was frequency. MedCity News described the Senza device as delivering high-frequency electrical pulses of up to 10,000 hertz to the spinal cord, a setting intended to avoid the tingling sensation known as paresthesia; at the time Nevro called the approach HF10 therapy. The company’s own website now uses the name “10 kHz Therapy” and says that traditional spinal cord stimulation had been around for more than 30 years before Nevro offered what it calls a next-generation approach.

The regulatory path ran through Europe first. Nevro says the Senza SCS system received the CE mark in 2010 and FDA approval in 2015, and that it is sold in Europe, Australia and the United States. MedCity News dated the first FDA approval to May 2015 and reported a further premarket approval in April 2016, which allowed surgical leads to be used with the Senza system.

The company was listed on the New York Stock Exchange, where its common stock traded until the morning of 3 April 2025, according to Globus Medical’s announcement of that date.

Senza, HFX and a growing list of indications.

Nevro’s product story is built around one system and one platform name. The hardware is the Senza spinal cord stimulation system; the wider offer is HFX, which Globus Medical’s April 2025 announcement described as Nevro’s comprehensive SCS platform, including the Senza system and support services, for chronic pain of the trunk and limbs and for painful diabetic neuropathy.

The HFX name arrived in 2021. In July 2021 the trade blog Implantable Device reported that the FDA had approved an additional indication for the Senza system, chronic pain associated with painful diabetic neuropathy, and quoted Nevro as saying it would begin selling it under its recently launched HFX branding, as “HFX for PDN.” Nevro said at the time that the approval was specific to its 10 kHz stimulation.

Nevro’s website today organises its offer for doctors under four headings — innovative technologies, advanced therapies, services and support, and what it calls meaningful evidence. Its provider pages name HFX AdaptivAI technology, a trial stimulator, and indications for painful diabetic neuropathy and what it calls non-surgical back pain, both of which the company says are specific FDA indications for its SCS system. The company also says that in the United States its SCS systems are approved to deliver all available SCS frequencies in a single product, alongside the 10 kHz setting that gave it its identity.

The range reaches beyond the spine’s stimulation leads. Globus Medical’s 2025 announcement noted that Nevro also offers minimally invasive treatment options for chronic sacroiliac joint pain, and the Nevro website carries a separate SI Joint section and separate safety pages for SCS and SIJ products.

The homepage speaks of individualised relief and of “expanding indications,” and the site’s menus list publications, product and patient manuals, reimbursement, grants and patient support resources alongside the product pages.

How neurotech presents itself.

Neuromodulation companies sell devices that most people will never see. Spinal cord stimulators, sacral nerve stimulators, hypoglossal nerve implants and brain-computer interfaces sit under the skin or inside the skull, so the companies that make them have to show something else: the scale of the device, the place it sits in the body, and the people it is meant for.

A few images recur across the category. Implants are often photographed held between fingertips or beside a coin or a key fob, to make their size legible. X-ray-style renders show thin leads running along a spine or curving toward a nerve, with the generator drawn as a small rounded shape. Patient pages tend to use calm portraits at home, on walks or with family, rather than hospital scenes.

Brain-computer interface start-ups lean in another direction: glowing renders of the brain, electrode arrays magnified many times over, and photographs of lab benches, engineers and surgical teams. Their audience includes investors and researchers as much as doctors, and the imagery often reads as a promise about the future rather than a product shot.

The category also has its own meeting places. Trade congresses such as the North American Neuromodulation Society (NANS) meeting, the International Neuromodulation Society (INS) congress and the Society for Neuroscience annual meeting are where companies show booths, posters and new hardware to clinicians and scientists. This guide sets out what can be checked about each company — founding, ownership, products and approvals as dated sources state them — and marks clearly what rests only on the company’s own word.

From a listed company to part of Globus Medical.

Nevro did not stay independent. Globus Medical, the musculoskeletal technology company based in Audubon, Pennsylvania, announced on 3 April 2025 that it had completed its previously disclosed acquisition of Nevro Corp. Nevro’s common stock stopped trading on the New York Stock Exchange before the market opened that day. Globus described Nevro as a global medical device company focused on the treatment of chronic pain and said the purchase expanded its presence in the musculoskeletal market and in neuromodulation; its chief executive, Dan Scavilla, spoke of accelerating the market penetration of Nevro’s high-frequency technology.

The name has survived the change of owner. In November 2026 the nevro.com website still presents Nevro and HFX as its own brand, with sites for the United States, an international English edition, Australia and a German-language edition, while the copyright line at the foot of each page names Globus Medical, Inc. or one of its subsidiaries. The about page still describes Nevro as a medical device company headquartered in Redwood City.

The website’s structure splits the audience in two, with separate sections for providers and for patients, and repeats a small set of names throughout: Senza, HFX and the “10 kHz” figure. In the trade press and in the company’s own words, the story is about one technical choice — the stimulation frequency — that became a product name.

For a design guide, Nevro shows how a medical device company can build its identity around one number and keep that identity inside a larger owner. Compare Medtronic, where Nevro’s chief executive from 2011 had been chief operating officer, and Saluda Medical, another spinal cord stimulation maker. For this guide we use a night navy, a lead teal and a pale clinic mist with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Nevro’s identity on hand — save it to a board in the Made Good inspiration library.